Clarithromycin provided effective therapy against arthritis induced by Borrelia burgdorferi infection in the hamster. In vitro, clarithromycin was at least 1 log more potent than tetracycline against two isolates of B.
Lyme borreliosis is the most commonly reported tickborne disease in Europe and the United States (4) . In the first half of 1992, the Centers for Disease Control reported over 2,000 confirmed cases of Lyme borreliosis (5) . However, because of difficulties in diagnosis (17, 19) , the actual incidence of the disease is unknown. Borrelia burgdorferi is the causative agent of Lyme disease.
Lyme disease presents a wide variety of clinical manifestations, which are often divided into stages. Lyme disease is initially characterized by a flu-like illness and a migrating rash termed erythema migrans. Cardiac or neurologic involvement may also occur. Arthritis is the most common serious and chronic manifestation of Lyme disease (8, 10, 23) . The knee joint is a frequent target of this arthritis, which may appear several months after erythema migrans. The progression and appearance of clinical signs may vary considerably among individuals. Treatment efficacy appears to vary with the severity of the arthritis and progression of the disease (3) .
Commonly used oral antimicrobial agents for the treatment of Lyme disease include tetracycline, doxycycline, erythromycin, and penicillin V. Oral antimicrobial agents have appeared to be relatively ineffective in treating Lyme disease arthritis (4, 6, 7, 22) . This situation, along with the long period required for antibiotics to kill B. burgdorferi in vitro (1, 16) and the chronic nature of the arthritis, suggests a need for effective oral antibiotics which are safe to administer on a long-term basis. The limited clinical trials support the need to investigate additional antimicrobial agents for their efficacy and safety in treatment of Lyme disease.
Several different animal models are used to simulate Lyme disease. Some laboratory animals do not manifest Lyme disease as arthritic joint swelling but instead suffer infections of various internal organs (17) . Recovery of the pathogen from internal organs can be difficult and is usually judged on a plus-or-minus basis rather than on a quantitative scale. The hamster model allows assessment of arthritic paw swelling as a measure of pathology (21) (2) .
Antimicrobial agents. The antimicrobial agents tested were tetracycline hydrochloride (Squibb, Princeton, N.J.), doxycycline (Geneva, Broomfield, Colo.), and clarithromycin and 14-hydroxy-clarithromycin (Abbott Laboratories, Abbott Park, Ill.).
In vitro susceptibility procedures. The 50% inhibitory concentrations (IC50s) of the study agents were determined by cultivating B. burgdorferi in BSK II medium both with and without the agents. Concentrations of the test antimicrobial agents ranged from 0.01 to 100 ,ug/ml. Tubes containing 1.0 ml of BSK II medium with the appropriately diluted antimicrobial agents and control tubes (no antimicrobial agent) were inoculated to a final density of 5 x 106 organisms per ml. The spirochetes were in the early log phase of growth. After incubation at 33°C for 48 h, the tubes were examined by dark-field microscopy for the presence of viable spirochetes. A total of 100 spirochetes from each tube were examined for the presence of motility. IC50s were calculated by linear regression. MICs were calculated as the lowest dilution yielding less than 5% viability.
In vivo susceptibility procedures (12 Recovery ofB. burgdorferi from organs. At the conclusions of trials, bladders, spleens, kidneys, and/or heart tissues were aseptically removed from the hamsters. The tissues were coarsely minced and individually incubated in 15 ml of BSK II medium per organ. The tubes were incubated at 33°C for up to 3 weeks. The cultures were examined by dark-field microscopy at weekly intervals for the presence of spirochetes.
Pharmacokinetics. The concentrations of clarithromycin, 14-hydroxy-clarithromycin, tetracycline, and doxycycline in hamster sera following a single 20-mg/kg subcutaneous dose was determined by bioassay (9) . Sera were collected 0.5, 1, 2, 3, 6, 8, 12, 16, and 24 h following administration of the dose. There were four hamsters tested per time point. 
RESULTS
In vitro susceptibility of the B. burgdorferi isolates to antimicrobial agents. The IC50s of clarithromycin (0.044 ,ug/ml) and the 14-hydroxy metabolite of clarithromycin (0.042 ,ug/ml) were lower in vitro than those of either tetracycline (1.960 ,ug/ml) or doxycycline (0.811 p,g/ml) against the pathogenic 297 strain ( Table 1 ). The IC50s were based upon viability curves of B. burgdorfen exposed to known concentrations of drugs. These curves represent typical dose susceptibility profiles for in vitro exposure to bactericidal compounds (Fig. 1 ). MICs were approximately 1 log greater than the corresponding IC50s. The German strain, which produces no pathology in the hamster, was also more susceptible to clarithromycin and the 14-hydroxy metabolite than to tetracycline or doxycycline. The German strain was more resistant to all four antibiotics and higher IC50s were obtained for each compound.
Antimicrobial treatment of B. burgdorferi-infected hamsters. The effect of early therapy on the increase in paw mass of hamsters infected with B. burgdorferi 297 is illustrated in Fig. 2 hamsters treated on days 1 to 7 with clarithromycin or doxycycline at 20 mg/kg. The numerical results of this trial are presented in Table 2 . The AUC values, calculated as milligrams days, indicated that clarithromycin or doxycycline at 20 mg/kg daily effectively prevented paw swelling in infected hamsters. Over the course of the trial, the AUC values for untreated infected hamsters were approximately three times greater than those for infected hamsters treated with clarithromycin at 20 mg/kg. Hamsters treated with clarithromycin or doxycycline at 10 mg/kg daily suffered a slight and transient swelling of the hind paws. The onset of this minimal swelling was not delayed, but there was a more rapid recovery (return to baseline values for paw mass) in the treated hamsters.
Clarithromycin and 14-hydroxy-clarithromycin yielded similar efficacies against B. burgdorferi 297 infection (Table   TABLE 3 3). There was some transient swelling in both groups of treated hamsters. There was a delay in time to maximal paw swelling from 7 days in untreated hamsters to 15 to 17 days in treated hamsters. Untreated hamsters had a mean paw mass (AUC) nearly five times that of hamsters treated with clarithromycin at 25 mg/kg. By day 20, the mean paw masses of all treated hamsters had returned to baseline (noninfected) values. Untreated hamsters had a mean paw mass that stabilized at approximately twice that of noninfected hamsters.
Clarithromycin was also effective when given on a twicedaily (b.i.d.) schedule (Table 4) . At 25 mg/kg b.i.d. (50-mg/kg total daily dose), clarithromycin prevented the onset of swelling due to B. burgdorferi infection. Similar efficacy was obtained with doxycycline. Untreated hamsters had a mean AUC value over four times that of noninfected hamsters. By the conclusion of the trial, the paw masses of all treated hamsters had returned to baseline values.
Clarithromycin therapy was also effective in reducing the severity of swelling and decreasing recovery time when given after the onset of swelling (Fig. 3 and Hamsters treated with clarithromycin beginning on day 6 (the first day on which swelling was apparent) had a mean AUC value during and after therapy (AUC from days 7 to 17 ) approximately 50% that of untreated hamsters. Prior to the start of therapy (AUCO-,6), the paw masses of all groups of infected hamsters were similar. There was similar efficacy in reducing peak paw swelling and overall mean paw mass with 25 and 12.5 mg of clarithromycin per kg daily. By the conclusion of the trial, the paw masses of treated hamsters had returned to values similar to those for noninfected hamsters, while untreated hamsters had a mean paw mass approximately twice that of noninfected hamsters (Fig.  3) .
Recovery of borreliae from treated hamsters. The recovery and cultivation of borreliae from hamster bladders, kidneys, hearts, or spleens at the conclusion of the trials (days 20 to 24 after inoculation) was not a useful indicator of drug efficacy. Untreated hamsters often did not yield detectable numbers of spirochetes. The recovery of B. burgdorferi was not used as an indicator of drug efficacy.
Titers of antibody to B. burgdorfieri in hamster sera. Hamster sera collected at the conclusion of the trial were assayed for anti-Borrelia antibody by using an immunofluorescentantibody test. There was no apparent difference between treated and untreated hamsters in the amount of anti-Borrelia antibody present at the trial's conclusion. Both drugtreated and untreated infected hamsters yielded immunofluorescent-antibody mean scores of 3.0 or greater, while noninfected hamsters yielded a mean score of 0.
Pharmacokinetic evaluation of anti-Borrelia compounds. A single 20-mg/kg dose of clarithromycin in hamsters yielded a maximum concentration of drug in serum (Cm,a) value of 2.098 ,ug/ml (Table 6) , which was well in excess of the concentration required to kill B. burgdorferi in vitro (IC50 = 0.044 ,ug/ml). The Cm,, AUCO-24, and half-life (t4/2) values were similar to those achieved clinically in humans (9) . A 20-mg/kg dose of the 14-hydroxy metabolite of clarithromycin, which is not produced in rodents, yielded Cm., AUCO_ 24 , and t1/2 values less than those for clarithromycin at equivalent doses. The Cm, of doxycycline was near the in vitro IC50 and less than the MIC of the drug. 
DISCUSSION
There is a need for systematic preclinical testing of potential anti-Borrelia compounds. In vitro, B. burgdorferi is susceptible to a number of agents, including macrolides, tetracyclines, and 1-lactam antibiotics (11, 13, (16) (17) (18) 20 (12, 14) .
The long exposure period required for antibiotics to kill B.
burgdorferi in vitro suggests that drugs with long t1/2 in serum may be effective therapeutic agents. The recommended tetracycline therapy of 250 mg four times daily (17a) produces serum drug concentrations that are less than the MICs reported by several laboratories (15) . Clarithromycin, with both superior in vitro potency against B. burgdorferi and promising in vivo pharmacokinetic parameters, including a biologically active metabolite in humans, merited preclinical testing. Clarithromycin and the 14-hydroxy metabolite of clarithromycin were over 1 log more potent in vitro than either tetracycline or doxycycline against B. burgdorferi 297. The use of IC50s rather than traditional MICs is appropriate for comparing the in vitro potencies of anti-B. burgdorferi compounds. The in vitro assay depends upon microscopic observation for the determination of spirochete viability. The most accurate calculation of drug potency occurs at the 50% point of the viability curve (Fig. 1) . The high potency of clarithromycin and the 14-hydroxy metabolite of clarithromycin suggests that effective serum drug concentrations could be maintained for longer periods in humans, since hamsters do not produce the metabolite.
Early treatment with clarithromycin or doxycycline prevented arthritic paw swelling (Fig. 2) . This effect was measured as both a decrease in maximal paw swelling and a reduction in the paw swelling over the course of the trial (Table 2) .
Therapy with 14-hydroxy-clarithromycin, a major metabolite in humans but not in hamsters, showed in vivo efficacy similar to that of clarithromycin. Additionally, compared with untreated controls, there was a 6-to 10-day delay in the time required to produce maximal paw swelling (Table 3) . (9) .
Clarithromycin therapy initiated after the onset of arthritis rapidly reduced both the maximal swelling and the duration of arthritis (Fig. 3 and 
